The causes of MDS remain poorly defined, but several studies have reported the NKT cell compartment of patients with MDS is deficient in number and functionally defective. In support of a central ...

A new study published in Mucosal Immunology shows that α-galactosylceramide (α-GalCer) serves as a potent adjuvant by activating natural killer T (NKT) cells, which promote effective cross ...

The Virtual Investor CEO Connect featuring GRI Bio is now available here. Additional videos from the “What This Means” series are available on demand at https://virtualinvestorco.com/gri/.

GRI Bio's focus on an innovative pipeline targeting Natural Killer T (NKT) cell modulators indicates a strategic approach to treating inflammatory and fibrotic diseases, suggesting long-term ...

About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are ...

More information: Tomoyoshi Tamura et al, Diverse NKT cells regulate early inflammation and neurological outcomes after cardiac arrest and resuscitation, Science Translational Medicine (2024). DOI ...

LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio” or the "Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT”) cell ...

(NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory ...

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of ...